vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and JOINT Corp (JYNT). Click either name above to swap in a different company.

Editas Medicine, Inc. is the larger business by last-quarter revenue ($24.7M vs $15.2M, roughly 1.6× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -22.7%, a 29.2% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -19.2%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-36.4M). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs -28.6%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.

EDIT vs JYNT — Head-to-Head

Bigger by revenue
EDIT
EDIT
1.6× larger
EDIT
$24.7M
$15.2M
JYNT
Growing faster (revenue YoY)
JYNT
JYNT
+22.2% gap
JYNT
3.1%
-19.2%
EDIT
Higher net margin
JYNT
JYNT
29.2% more per $
JYNT
6.5%
-22.7%
EDIT
More free cash flow
JYNT
JYNT
$36.8M more FCF
JYNT
$334.7K
$-36.4M
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
-28.6%
JYNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EDIT
EDIT
JYNT
JYNT
Revenue
$24.7M
$15.2M
Net Profit
$-5.6M
$991.1K
Gross Margin
81.4%
Operating Margin
-31.3%
4.9%
Net Margin
-22.7%
6.5%
Revenue YoY
-19.2%
3.1%
Net Profit YoY
87.6%
5510.5%
EPS (diluted)
$0.03
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
JYNT
JYNT
Q4 25
$24.7M
$15.2M
Q3 25
$7.5M
$13.4M
Q2 25
$3.6M
$13.3M
Q1 25
$4.7M
$13.1M
Q4 24
$30.6M
$14.7M
Q3 24
$61.0K
$30.2M
Q2 24
$513.0K
$30.3M
Q1 24
$1.1M
$29.7M
Net Profit
EDIT
EDIT
JYNT
JYNT
Q4 25
$-5.6M
$991.1K
Q3 25
$-25.1M
$855.0K
Q2 25
$-53.2M
$93.4K
Q1 25
$-76.1M
$967.8K
Q4 24
$-45.4M
$17.7K
Q3 24
$-62.1M
$-3.2M
Q2 24
$-67.6M
$-3.6M
Q1 24
$-62.0M
$947.0K
Gross Margin
EDIT
EDIT
JYNT
JYNT
Q4 25
81.4%
Q3 25
80.1%
Q2 25
79.1%
Q1 25
77.3%
Q4 24
78.4%
Q3 24
90.7%
Q2 24
90.7%
Q1 24
90.9%
Operating Margin
EDIT
EDIT
JYNT
JYNT
Q4 25
-31.3%
4.9%
Q3 25
-325.4%
1.2%
Q2 25
-1440.6%
-8.6%
Q1 25
-1635.1%
-5.2%
Q4 24
-152.2%
5.5%
Q3 24
-107649.2%
-1.6%
Q2 24
-14016.2%
-5.9%
Q1 24
-5902.3%
-1.4%
Net Margin
EDIT
EDIT
JYNT
JYNT
Q4 25
-22.7%
6.5%
Q3 25
-333.0%
6.4%
Q2 25
-1487.8%
0.7%
Q1 25
-1633.5%
7.4%
Q4 24
-148.3%
0.1%
Q3 24
-101870.5%
-10.5%
Q2 24
-13178.8%
-11.9%
Q1 24
-5458.1%
3.2%
EPS (diluted)
EDIT
EDIT
JYNT
JYNT
Q4 25
$0.03
$0.06
Q3 25
$-0.28
$0.06
Q2 25
$-0.63
$0.01
Q1 25
$-0.92
$0.06
Q4 24
$-0.55
$0.01
Q3 24
$-0.75
$-0.21
Q2 24
$-0.82
$-0.24
Q1 24
$-0.76
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
JYNT
JYNT
Cash + ST InvestmentsLiquidity on hand
$146.6M
$23.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$15.1M
Total Assets
$186.5M
$61.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
JYNT
JYNT
Q4 25
$146.6M
$23.6M
Q3 25
$165.6M
$29.7M
Q2 25
$178.5M
$29.8M
Q1 25
$221.0M
$21.9M
Q4 24
$269.9M
$25.1M
Q3 24
$265.1M
$20.7M
Q2 24
$279.1M
$17.5M
Q1 24
$296.2M
$18.7M
Total Debt
EDIT
EDIT
JYNT
JYNT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EDIT
EDIT
JYNT
JYNT
Q4 25
$27.3M
$15.1M
Q3 25
$13.5M
$22.7M
Q2 25
$19.2M
$23.2M
Q1 25
$62.4M
$22.8M
Q4 24
$134.3M
$20.7M
Q3 24
$175.6M
$20.5M
Q2 24
$232.0M
$23.2M
Q1 24
$294.4M
$26.2M
Total Assets
EDIT
EDIT
JYNT
JYNT
Q4 25
$186.5M
$61.0M
Q3 25
$201.8M
$69.4M
Q2 25
$210.6M
$73.2M
Q1 25
$263.7M
$80.1M
Q4 24
$341.6M
$83.2M
Q3 24
$327.6M
$79.6M
Q2 24
$384.8M
$82.4M
Q1 24
$440.3M
$85.7M
Debt / Equity
EDIT
EDIT
JYNT
JYNT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
JYNT
JYNT
Operating Cash FlowLast quarter
$-36.4M
$1.8M
Free Cash FlowOCF − Capex
$-36.4M
$334.7K
FCF MarginFCF / Revenue
-147.3%
2.2%
Capex IntensityCapex / Revenue
0.2%
9.9%
Cash ConversionOCF / Net Profit
1.86×
TTM Free Cash FlowTrailing 4 quarters
$-1.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
JYNT
JYNT
Q4 25
$-36.4M
$1.8M
Q3 25
$-30.8M
$1.8M
Q2 25
$-50.2M
$868.6K
Q1 25
$-47.8M
$-3.7M
Q4 24
$-50.8M
$9.4M
Q3 24
$-52.6M
$3.4M
Q2 24
$-57.1M
$-973.5K
Q1 24
$-49.9M
$2.8M
Free Cash Flow
EDIT
EDIT
JYNT
JYNT
Q4 25
$-36.4M
$334.7K
Q3 25
$-31.3M
$1.5M
Q2 25
$363.6K
Q1 25
$-47.9M
$-4.0M
Q4 24
$-51.3M
$8.2M
Q3 24
$-55.5M
$3.2M
Q2 24
$-60.6M
$-1.2M
Q1 24
$-51.7M
$2.4M
FCF Margin
EDIT
EDIT
JYNT
JYNT
Q4 25
-147.3%
2.2%
Q3 25
-414.6%
10.9%
Q2 25
2.7%
Q1 25
-1028.6%
-30.8%
Q4 24
-167.6%
55.9%
Q3 24
-90998.4%
10.6%
Q2 24
-11804.3%
-4.1%
Q1 24
-4558.9%
8.1%
Capex Intensity
EDIT
EDIT
JYNT
JYNT
Q4 25
0.2%
9.9%
Q3 25
5.7%
2.4%
Q2 25
0.0%
3.8%
Q1 25
2.4%
2.5%
Q4 24
1.8%
8.1%
Q3 24
4788.5%
0.8%
Q2 24
681.1%
0.9%
Q1 24
164.8%
1.3%
Cash Conversion
EDIT
EDIT
JYNT
JYNT
Q4 25
1.86×
Q3 25
2.07×
Q2 25
9.30×
Q1 25
-3.82×
Q4 24
532.98×
Q3 24
Q2 24
Q1 24
2.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EDIT
EDIT

Segment breakdown not available.

JYNT
JYNT

Transferred At Point In Time$12.8M84%
Transferred Over Time$2.4M16%

Related Comparisons